Possible trigger for autoimmune diseases discovered: B cells teach T cells which targets must not be attacked
While it is not yet known which molecules are attacked in MS, it is well-established that T cells respond to the protein AQP4 ...
Hosted on MSN10mon
FDA grants approval for Alexion’s NMOSD treatment
The US Food and Drug Administration (FDA) has approved Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab-cwvz) to treat adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+ ...
pharmaphorum8d
Roche takes on Alexion as FDA approves satralizumab in NMOSD
The big Swiss pharma had been hoping for approval in patients regardless of whether they have anti-aquaporin-4 (AQP4) antibodies. But so far Roche has not produced enough data in the broader ...
pharmaphorum1y
Positive new phase 3 MRI data from UPLIZNA trial for NMOSD
Approximately 80% of all patients with NMOSD test positive for anti-AQP4 antibodies. During the phase 3 trial, MRI imaging was conducted on the spinal cord, optic nerve, and brain/brain stem to ...